Brodie AMH, Schwarzel WC, Shaikh AA, Brodie HJ: The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene-3,17-Dione, on Estrogen Dependent Processes in Reproduction and Breast Cancer. Endocrinology, 100:1684-1695, 1977.
Coombes CR, Goss P, Dowsett M, Gazet JC, Brodie A: 4-Hydroxyandostenedione in Treatment of Postmenopausal Patients with Advanced Breast Cancer. Lancet, 2:1237-1239, 1984
Goss PE, Coombes RL, Powles TJ, Dowsett M, Brodie AMH: Treatment of Advanced Postmenopausal Breast Cancer with Aromatase Inhibitor, 4-Hydroxyandrostenedione-Phase 2 Report. Cancer Res, 46:4823-4826, 1986.
Njar VCO, Brodie AMH: Inhibitors of 17á-Hydroxylase/C17,20-Lyase (CYP17): Potential Agents for the Treatment of Prostate Cancer. Current Pharm Design, 5:163-180, 1999
Nnane IP, Kato K, Liu Y, Long BJ, Lu Q, Wang X, Ling YZ, Brodie AMH: Inhibition of Androgen Synthesis in Human Testicular and Prostatic Microsomes and in Male Rats by Novel Steroidal Compounds. Endocrinology, 140:2891-2897,1999
Long B, Grigoryev D, Nnane I, Liu Y, Ling YZ, Brodie A: Antiandrogen Effects of Novel Inhibitors of Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer. Cancer Res, 60:6630-6640, 2000.
Brodie A: Aromatase Inhibitors and the Application to the Treatment of Breast Cancer. In: Breast Cancer: Prognosis, Treatment and Prevention, ed. Jorge Pasqualini, Chapter 8, pp. 251-270, 2002, Marcel Dekker, NY.
Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Brodie AM: Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model. JNCI 96:456-465,2004.